These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 27449546)

  • 61. Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors.
    Goldfarb DS; MacDonald PA; Hunt B; Gunawardhana L
    J Rheumatol; 2011 Jul; 38(7):1385-9. PubMed ID: 21572152
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dual-Energy Computed Tomography Imaging Study Within a Randomized, Controlled Trial.
    Dalbeth N; Billington K; Doyle A; Frampton C; Tan P; Aati O; Allan J; Drake J; Horne A; Stamp LK
    Arthritis Rheumatol; 2019 Oct; 71(10):1739-1746. PubMed ID: 31081595
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.
    Yu KH; Lai JH; Hsu PN; Chen DY; Chen CJ; Lin HY
    Scand J Rheumatol; 2016 Jul; 45(4):304-11. PubMed ID: 26771445
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Long-Term Follow-up of a Randomized Controlled Trial of Allopurinol Dose Escalation to Achieve Target Serum Urate in People With Gout.
    Coleman GB; Dalbeth N; Frampton C; Haslett J; Drake J; Su I; Horne AM; Stamp LK
    J Rheumatol; 2022 Dec; 49(12):1372-1378. PubMed ID: 35777814
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions.
    Chohan S
    J Rheumatol; 2011 Sep; 38(9):1957-9. PubMed ID: 21724706
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
    Sundy JS; Baraf HS; Yood RA; Edwards NL; Gutierrez-Urena SR; Treadwell EL; Vázquez-Mellado J; White WB; Lipsky PE; Horowitz Z; Huang W; Maroli AN; Waltrip RW; Hamburger SA; Becker MA
    JAMA; 2011 Aug; 306(7):711-20. PubMed ID: 21846852
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Presence of monosodium urate crystal deposition by dual-energy CT in patients with gout treated with allopurinol.
    Dalbeth N; Nicolaou S; Baumgartner S; Hu J; Fung M; Choi HK
    Ann Rheum Dis; 2018 Mar; 77(3):364-370. PubMed ID: 29146741
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Gout.
    Dalbeth N; Choi HK; Joosten LAB; Khanna PP; Matsuo H; Perez-Ruiz F; Stamp LK
    Nat Rev Dis Primers; 2019 Sep; 5(1):69. PubMed ID: 31558729
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
    Reinders MK; van Roon EN; Jansen TL; Delsing J; Griep EN; Hoekstra M; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jan; 68(1):51-6. PubMed ID: 18250112
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationale.
    Saddekni MB; Saag KG; Dudenbostel T; Oparil S; Calhoun DA; Sattui SE; Feig DI; Muntner P; Redden DT; Foster PJ; Rahn EJ; Biggers SR; Li P; Gaffo AL
    Contemp Clin Trials; 2016 Sep; 50():238-44. PubMed ID: 27587282
    [TBL] [Abstract][Full Text] [Related]  

  • 71. GOSPEL 3: Management of gout by primary-care physicians and office-based rheumatologists in France in the early 21st century - comparison with 2006 EULAR Recommendations.
    Goossens J; Lancrenon S; Lanz S; Ea HK; Lambert C; Guggenbuhl P; Saraux A; Delva C; Sahbane S; Lioté F
    Joint Bone Spine; 2017 Jul; 84(4):447-453. PubMed ID: 28411137
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations.
    Roddy E; Zhang W; Doherty M
    Ann Rheum Dis; 2007 Oct; 66(10):1311-5. PubMed ID: 17504843
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Understanding and improving the use of allopurinol in a teaching hospital.
    Hmar RC; Kannangara DR; Ramasamy SN; Baysari MT; Williams KM; Day RO
    Intern Med J; 2015 Apr; 45(4):383-90. PubMed ID: 25644128
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Lack of effect of tart cherry concentrate dose on serum urate in people with gout.
    Stamp LK; Chapman P; Frampton C; Duffull SB; Drake J; Zhang Y; Neogi T
    Rheumatology (Oxford); 2020 Sep; 59(9):2374-2380. PubMed ID: 31891407
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.
    Stamp LK; Taylor WJ; Jones PB; Dockerty JL; Drake J; Frampton C; Dalbeth N
    Arthritis Rheum; 2012 Aug; 64(8):2529-36. PubMed ID: 22488501
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Facilitating equitable prevention and management of gout for Māori in Northland, New Zealand, through a collaborative primary care approach.
    Lawrence A; Scott S; Saparelli F; Greville G; Miller A; Taylor A; Gow P
    J Prim Health Care; 2019 Jul; 11(2):117-127. PubMed ID: 32171354
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand.
    Stamp LK; Haslett J; Frampton C; White D; Gardner D; Stebbings S; Taylor G; Grainger R; Kumar R; Kumar S; Kain T; Porter D; Corkill M; Cathro A; Metcalfe S; Wyeth J; Dalbeth N
    Intern Med J; 2016 Sep; 46(9):1075-80. PubMed ID: 27391386
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Evaluating appropriate use of prophylactic colchicine for gout flare prevention.
    George M; Pullman-Mooar S; Hussain F; Schumacher HR
    Arthritis Care Res (Hoboken); 2014 Aug; 66(8):1258-62. PubMed ID: 24376081
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Serum urate levels and therapy in adults treated with long-term dialysis: a retrospective cross-sectional study.
    Yeo E; Palmer SC; Chapman PT; Frampton C; Stamp LK
    Intern Med J; 2019 Jul; 49(7):838-842. PubMed ID: 30426652
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Management of Gout in a Hospital Setting: A Lost Opportunity.
    Wright S; Chapman PT; Frampton C; O'Donnell JL; Raja R; Stamp LK
    J Rheumatol; 2017 Oct; 44(10):1493-1498. PubMed ID: 28765252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.